Syringe Exchange Research Update Harm Reduction Coalition August 2008
|
|
- Kathlyn Garrett
- 5 years ago
- Views:
Transcription
1 Syringe Exchange Research Update August 2008 Introduction This overview and annotated bibliography summarizes key recent research on syringe exchange programs in the United States and related data on injection drug users, HIV, and hepatitis C published after Findings continue to support the effectiveness of syringe exchange, corroborated by declines in HIV incidence and hepatitis C prevalence among injection drug users in the U.S. Additional research characterizes dynamics and mediators of injection-related risk, assesses coverage levels of syringe exchange programs, and examines the role and impact of ancillary services at syringe exchange sites such as HIV testing, hepatitis B vaccination, and referral to substance abuse treatment. Overview The majority of research on the effectiveness of syringe exchange programs (SEPs) in the United States was conducted and published in the 1990s. These findings have been summarized in numerous reports and reviews, and provide conclusive evidence that syringe exchange reduces injection-related HIV risks (e.g. syringe sharing) without increasing drug use among SEP participants, nor do SEPs result in other negative consequences (e.g. improperly discarded syringes, crime). The most recent and comprehensive review of evidence for the effectiveness of syringe exchange was conducted for the World Health Organization and published in 2004 as part of WHO s Evidence for Action series. A 2006 article synthesized the findings related to HIV prevention (Wodak and Cooney, Do Needle Syringe Programs Reduce HIV Infection Among Injecting Drug Users: A Comprehensive Review of the International Evidence ). A 2008 commentary provides context for these assessments, describing lessons for programs and policymakers on HIV prevention for injection drug users (Des Jarlais and Semaan, HIV Prevention for Injecting Drug Users: The First 25 Years and Counting ). A 2007 report in the CDC s Morbidity and Mortality Weekly offers a current snapshot of SEPs in the United States based on a 2005 national survey, with an analysis of size and scope of programs, services offered, and funding sources (CDC, Syringe exchange programs -- United States, 2005 ). Recent epidemiological studies have attempted to quantify and describe the injection drug user population in the United States, estimating roughly 1.5 million injection drug users nationally (Brady JE, et al., Estimating the prevalence of injection drug users in the U.S. New York Office 22 West 27 th Street, 5 th Floor New York, NY fax: hrc@harmreduction.org website: H A R M R E D U C T I O N C O A L I T I O N Oakland Office 1440 Broadway, Suite 510 Oakland, CA fax: hrcwest@harmreduction.org website:
2 and in large U.S. metropolitan areas from 1992 to 2002 ). Additionally analyses describe injection drug users as an aging population (Armstrong GL, Injection drug users in the United States, : an aging population ), and note declines in the numbers of black injection drug users relative to white injectors (Cooper HL, et al., Estimating the Prevalence of Injection Drug Use among Black and White Adults in Large U.S. Metropolitan Areas over Time [ ]: Estimation Methods and Prevalence Trends ; Broz and Ouellet, Racial and ethnic changes in heroin injection in the United States: implications for the HIV/AIDS epidemic ). Mounting epidemiologic data points to an overall decline in new HIV infections among injection drug users (IDUs) over the past 20 years in the United States, with parallel but more modest decline in hepatitis C rates. The newly released revised HIV incidence estimates from the CDC projected that in 2006, injection drug use accounted for 6,600 HIV infections in the 50 U.S. states and Washington, DC (excluding Puerto Rico), with an additional 2,100 new infections among men who have sex with men (MSM) who also report injecting drugs. The authors note: Overall, HIV incidence among individuals exposed through IDU has decreased approximately 80% in the United States. Over that time, those exposed through IDU have reduced needle sharing by using sterile syringe available through needle exchange programs or pharmacies and have reduced the number of individuals with whom they share needles. (Hall et al., Estimation of HIV Incidence in the United States ). Similar declines in hepatitis C prevalence among IDUs, though lesser in magnitude, have been reported in several U.S. cities with SEPs (e.g., Amon et al., Prevalence of hepatitis C virus infection among injection drug users in the United States, ). Given that the fundamental questions about the effectiveness of SEPs in HIV prevention have long been considered resolved by the scientific and public health communities in the United States, much of the recent research on syringe exchange by U.S. researchers has shifted to focus on international settings, particularly in countries in Asia, Eastern Europe and the former Soviet Union where explosive HIV/AIDS epidemics are driven by injection drug use. A few new U.S.-based studies provide additional corroboration of the evidence base supporting syringe exchange and contribute to knowledge on factors influencing injection-related risks, and one recent directly demonstrated the effectiveness of SEPs in reducing HIV risk (Huo and Ouellet, Needle exchange and injection-related risk behaviors in Chicago: a longitudinal study ). Other studies have evaluated ancillary services provided by SEPs and related health benefits (HIV testing, entry to substance abuse treatment). Important new analyses on syringe exchange and injection drug use in the U.S. have examined questions of coverage (how many syringes are exchanged and how many people are reached,
3 relative to need based on estimated size of injection drug user population).coverage is an emerging concept in SEP research that attempts to calculate the extent of syringe exchange (whether measured by proportion of IDUs reached, or numbers of syringes distributed relative to need) necessary to make an impact on HIV transmission rates. The World Health Organization recommends that SEPs strive to reach at least 60% of IDU populations, while the U.S. Public Health Service has long recommended using one new syringe for each injection. However, these levels of coverage have never been met in the United States even in localities with well-established SEPs with strong community and government support. In large part, the coverage gap reflects the impact of the federal funding ban in constraining resources that limit the sites and hours of operation of SEPs. However, epidemiologic data suggests that even more modest syringe coverage levels can have a significant impact on HIV epidemics among IDUs, though higher coverage levels associated with the availability of government funding for SEPs -- are correlated with lower HIV risks and greater decreases in AIDS diagnoses among IDUs. Annotated Bibliography General/Reviews/Epidemiology Wodak A, Cooney A. Do needle syringe programs reduce HIV infection among injecting drug users: a comprehensive review of the international evidence. Subst Use Misuse. 2006;41(6-7): See also: Wodak A. Lessons from the first international review of the evidence for needle syringe programs: the band still plays on. Subst Use Misuse. 2006;41(6-7): Des Jarlais DC, Semaan S. HIV prevention for injecting drug users: the first 25 years and counting. Psychosom Med Jun;70(5): Centers for Disease Control and Prevention (CDC). Syringe exchange programs -- United States, MMWR Morb Mortal Wkly Rep Nov 9;56(44): Hall HI, et al. Estimation of HIV incidence in the United States. JAMA Aug 6;300(5): Amon JJ, et al. Prevalence of hepatitis C virus infection among injection drug users in the United States, Clin Infect Dis Jun 15;46(12):
4 Brady JE, et al. Estimating the prevalence of injection drug users in the U.S. and in large U.S. metropolitan areas from 1992 to J Urban Health May;85(3): Armstrong GL. Injection drug users in the United States, : an aging population. Arch Intern Med Jan 22;167(2): Cooper HL, et al. Estimating the Prevalence of Injection Drug Use among Black and White Adults in Large U.S. Metropolitan Areas over Time ( ): Estimation Methods and Prevalence Trends. J Urban Health Aug 16. [Epub ahead of print] Broz D, Ouellet LJ. Racial and ethnic changes in heroin injection in the United States: implications for the HIV/AIDS epidemic. Drug Alcohol Depend Apr 1;94(1-3): Risk and Impact Huo D, Ouellet LJ. Needle exchange and injection-related risk behaviors in Chicago: a longitudinal study. J Acquir Immune Defic Syndr May 1;45(1): A study of 901 Chicago IDUs compared changes in risk between those recruited from an SEP and those recruited from an area with no SEP coverage; all study participants received a standard behavioral HIV prevention intervention. SEP use substantially reduced the likelihood of syringe sharing, and the impact of SEP participation on risk reduction was greater than the effect of the behavioral intervention alone. Neaigus A, et al. Greater drug injecting risk for HIV, HBV, and HCV infection in a city where syringe exchange and pharmacy syringe distribution are illegal. J Urban Health May;85(3): Compared injection risk and infection rates among 526 IDUs in New York City (where syringe exchange and pharmacy sale are legal) to Newark, NJ (where both forms of syringe access have been illegal until a recent change in New Jersey law allowing syringe exchange). Newark IDUs had substantially higher rates of HIV, hepatitis B, and hepatitis C infection compared to New York City IDUs (26% vs. 5%, 70% vs. 27%, and 82% vs. 53%, respectively). Newark IDUs were also more likely to report sharing syringes and less likely to obtain syringes from SEPs or pharmacies than NYC IDUs.
5 Burt RD, et al. Trends in hepatitis B virus, hepatitis C virus, and human immunodeficiency virus prevalence, risk behaviors, and preventive measures among Seattle injection drug users aged years, J Urban Health May;84(3): Analyzed studies of young IDUs in Seattle, WA over the course of a decade for changes in infection rates and risk. Hepatitis B and hepatitis C rates declined substantially (from 43% to 15%, and from 68% to 32%, respectively) and HIV prevalence remained very low (2-3%). While no trends were observed in overall injection-related risks, the proportion reporting SEPs as their primary syringe source increased significantly from 48% in 1994 to 68% in Coffin PO, et al. Safe syringe disposal is related to safe syringe access among HIV-positive injection drug users. AIDS Behav Sep;11(5): Assessed syringe access and disposal practices among 680 HIV+ IDUs in three U.S. cities. Nearly three-quarters had ever visited an SEP. 52% reported safe syringe access sources (e.g., obtained from SEP or pharmacy), and 31% reported possibly safe syringe access (e.g., obtained from friend who had visited an SEP) vs. 18% reporting unsafe syringe sources (e.g. bought from street dealer). IDUs who had ever visited an SEP and those obtaining syringes from safe sources were significantly more likely to dispose of their syringes safely. Des Jarlais DC, Braine N, Friedmann P. Unstable housing as a factor for increased injection risk behavior at US syringe exchange programs. AIDS Behav Nov;11(6 Suppl): Analysis of participants of 15 moderate-to-large sized SEPs across the U.S. with at least 50 survey subjects reporting recent unstable housing or homelessness. Unstably housed IDUs were twice as likely to report syringe sharing as stably housed IDUs participating in SEP. Des Jarlais DC, et al. Residual injection risk behavior, HIV infection, and the evaluation of syringe exchange programs. AIDS Educ Prev Apr;19(2): Surveyed participants of 6 large SEPs across the U.S. Between 10% and 27% of SEP participants at each program reported recent syringe sharing. Programs with higher HIV rates among participants had lower proportions of recent syringe sharing.
6 CIDUS/DUIT Papers Bailey SL, et al. Perceived risk, peer influences, and injection partner type predict receptive syringe sharing among young adult injection drug users in five U.S. cities. Drug Alcohol Depend Nov;91 Suppl 1:S Golub ET, et al. Distributive syringe sharing among young adult injection drug users in five U.S. cities. Drug Alcohol Depend Nov;91 Suppl 1:S30-8. Thiede H, et al. Prevalence and correlates of indirect sharing practices among young adult injection drug users in five U.S. cities. Drug Alcohol Depend Nov;91 Suppl 1:S These three papers report findings on injection-related risk from a large survey of young adult IDUs in five U.S. cities (Collaborative Injection Drug Users Study III/Drug Users Intervention Trial, or CIDUS/DUIT). The research found high levels of receptive syringe sharing (over half injected with a syringe that had previously been used by someone else), distributive syringe sharing (nearly half gave another IDU a syringe that they had previously used), and indirect sharing (over half reported sharing of injection equipment other than syringes, such as cookers and cotton, or splitting drugs with a common syringe). However, 76.9% reported obtaining most of their syringes from SEPs or pharmacies, and this group was significantly less likely to report receptive syringe sharing or distributive syringe sharing than those IDUs obtaining syringes primarily from other sources. Despite the levels of injection-related risk reported, only 2.8% were HIV positive a rate well below the overall average HIV prevalence among IDUs across the 5 cities and 34.3% had been infected with hepatitis C (a figure well in range of available epidemiological data for this subpopulation, and still lower than most of the hepatitis C prevalence rates reported for the general IDU population). Also of note, a subsequent behavioral intervention component of the study (DUIT) successfully resulted in further reducing injection-related risks among participants. Coverage Tempalski B, et al. Correlates of syringe coverage for heroin injection in 35 large metropolitan areas in the US in which heroin is the dominant injected drug. Int J Drug Policy Apr;19 Suppl 1:S47-58.
7 Assessed syringe coverage per heroin injector in cities with SEPs. Average coverage was estimated at only 3 syringes per 100 injections, though coverage rates varied widely. Cities with older SEP programs and larger MSM populations had greater syringe coverage. Government funding (city, county, and/or state) was associated with higher coverage levels, supporting arguments to lift the federal funding ban on SEPs. Heimer R. Community coverage and HIV prevention: assessing metrics for estimating HIV incidence through syringe exchange. Int J Drug Policy Apr;19 Suppl 1:S Compared syringe coverage through SEPs (percentage of IDUs reached, or percent of syringes provided per injection) in two cities: Chicago, IL and New Haven, CT. In both cities, programs generally reached less than 10% of their estimated IDU populations each month, and had low levels of coverage compared to syringe need. Coverage rates were higher in Chicago, where SEPs had less restrictive exchange policies than in New Haven. Despite modest coverage levels, the proportion of AIDS diagnoses attributed to IDUs declined by 21.7% in New Haven and by 41.4% in Chicago, suggesting a significant impact on HIV transmission. Bluthenthal RN, et al. Examination of the association between syringe exchange program (SEP) dispensation policy and SEP client-level syringe coverage among injection drug users. Addiction Apr;102(4): Evaluated the impact of different syringe dispensation policies on achieving adequate syringe coverage (defined as one new syringe per injection) for SEP participants (24 SEPs in California, 1576 IDUs). Results: IDUs were most likely to obtain adequate numbers of syringes from programs with the least restrictive policies (unlimited needs-based distribution models, vs. limited and/or one-for-one exchange models). Bluthenthal RN, et al. Higher syringe coverage is associated with lower odds of HIV risk and does not increase unsafe syringe disposal among syringe exchange program clients. Drug Alcohol Depend Jul 10;89(2-3): Evaluated the impact of syringe coverage (defined as one new syringe per injection) on HIV risk and unsafe syringe disposal among SEP participants (24 SEPs in California, 1577 IDUs). Results: IDUs with the highest levels of syringe coverage were least likely to share syringes, while IDUs with the lowest levels of syringe coverage were most likely to share syringes. Coverage levels did not have an impact on rates of safe syringe disposal i.e.,
8 IDUs receiving more syringes were no more likely to dispose of their syringes unsafely than IDUs receiving the fewest syringes. Other Services/Health Benefits Heimer R, et al. Assessment of HIV testing of urban injection drug users: implications for expansion of HIV testing and prevention efforts. Am J Public Health Jan;97(1): Surveyed HIV testing rates among 1543 IDUs in five cities. Overall, 93% of IDUs had ever been tested for HIV; among those not reporting a positive HIV test, 90% had been tested for HIV within the past 3 years. SEP participants were more likely both to have ever been tested and to have been tested recently. Heinzerling KG, et al. Human immunodeficiency virus and hepatitis C virus testing services at syringe exchange programs: availability and outcomes. J Subst Abuse Treat Jun;32(4): Surveyed 24 California SEPs. 62% provided both HIV and hepatitis C testing; 21% offered only HIV testing; 17% had no testing services available. Utilization of HIV and hepatitis C testing by SEP participants varied, but was greater in programs operating with official legal authorization. Hu Y, et al. Economic evaluation of delivering hepatitis B vaccine to injection drug users. Am J Prev Med Jul;35(1): Assigned 1,964 IDU participants in SEPs in Chicago, IL and Hartford and Bridgeport, CT to two different hepatitis B vaccination schedules. Hepatitis B vaccination through SEPs was found to be feasible and cost-saving. Neufeld K, et al. A comparison of 1-year substance abuse treatment outcomes in community syringe exchange participants versus other referrals. Drug Alcohol Depend Sep 1;97(1-2): Compared the results of substance abuse treatment among 324 methadone maintenance patients referred from SEPs vs. other referral sources. While those referred from SEPs were more likely to screen positive for opioid and cocaine use during treatment and less likely to complete 12 months of treatment when compared to
9 patients referred from other sources, those differences were attributed to the greater baseline addiction severity among SEP referrals. When baseline factors were factored in to the analysis, outcomes did not differ significantly between SEP referrals and referrals to treatment from other sources. Prepared by the, August 2008
Narrative Science-based literature on Syringe Exchange Programs (SEPs)
Narrative Science-based literature on Syringe Exchange Programs (SEPs) 1996 2007 Background: In 1988, the US Department of Health and Human Services (HHS) prohibited the use of federal money to be used
More informationHarm Reduction 10/17/2018. Topics for Today. Working Definition of Harm Reduction
Harm Reduction Dennis Radloff Human Services Program Coordinator Substance Abuse Services Topics for Today Overview of harm reduction Sterile syringe access programs Preventing fatal opioid overdoses Working
More informationSyringe Exchange Programs December 2005
Syringe Exchange Programs December 2005 In 1997, a Report to Congress concluded that needle exchange programs can be an effective component of a comprehensive strategy to prevent HIV and other blood-borne
More informationBackground. Population/Intervention(s)/ Comparison/Outcome(s) (PICO)
updated 2012 Role of sterile injection equipment and outreach programmes for injecting drug users Q 6. Does the provision of sterile injection equipment to injecting drug users reduce injecting related
More informationU.S. Counties Vulnerability to Rapid Dissemination of HIV/HCV Infections Among People Who Inject Drugs
U.S. Counties Vulnerability to Rapid Dissemination of HIV/HCV Infections Among People Who Inject Drugs Michelle Van Handel, MPH Health Scientist National Center for HIV/AIDS, Viral Hepatitis, STDs and
More informationOverview of Syringe Exchange Programs. New York City Police Academy November 24, 2004
Overview of Syringe Exchange Programs New York City Police Academy November 24, 2004 History of Syringe Exchange n Title 10 N.Y.C.R.R. 80.131 (a) (2), 80.135. n Enacted in 1992 in response to the HIV/AIDS
More informationEvidence-based findings on the efficacy of syringe exchange programs: an analysis of the scientific research completed since April 1998
U.S. Department of Health and Human Services Washington, DC March 17, 2000 Evidence-based findings on the efficacy of syringe exchange programs: an analysis of the scientific research completed since April
More informationTri-County Region Opioid Trends Clackamas, Multnomah, and Washington, Oregon. Executive Summary
Tri-County Region Opioid Trends Clackamas, Multnomah, and Washington, Oregon 2016 Executive Summary 20.8 million people in the United States have a substance use disorder (not limited to opioids), equivalent
More informationSaskatchewan HIV Strategy: Social Network Approach
Saskatchewan HIV Strategy: Social Network Approach Dr. Johnmark Opondo MHO Provincial Leadership Team (PLT) CATIE Forum: New Science, New Directions in HIV and HCV September 18, 2013 Toronto, Canada A
More informationwho use drugs in order to assist them in reducing harm while in the cycle of addiction
August 16, 2016 } Accepts that illicit drug use is part of our world, and chooses to minimize its harmful effects rather than ignore or condemn them } Calls for the provision of services to people who
More informationPresenters. Session Objectives. Session Overview. Cluster Investigations in Rural Wisconsin
Public Health Nurses, Hepatitis C, Injection Drug Use and Heroin Sheila Guilfoyle Viral Hepatitis Prevention Coordinator Division of Public Health Wisconsin Department of Health Services Wisconsin Public
More information5/2/2016. Dr Brooks has no relevant financial affiliations to disclose. (Update 04/15/16) Learning Objectives
Persistent Challenge of HIV Transmission Control in Injection Drug Use: The Indiana Outbreak John T. Brooks, MD Senior Medical Advisor, Division of HIV/AIDS Prevention National Center for HIV/AIDS, Viral
More informationObstacles and Opportunities on Our Path Toward Eliminating Viral Hepatitis
Obstacles and Opportunities on Our Path Toward Eliminating Viral Hepatitis Jonathan Mermin, MD, MPH National Center for HIV/AIDS, Viral Hepatitis, STD and TB Prevention Centers for Disease Control and
More informationOutline. Successful Integration of Hepatitis Vaccination Services into Programs for High-Risk Adults An Update of State-Based Programs
Successful Integration of Hepatitis Vaccination Services into Programs for High-Risk Adults An Update of State-Based Programs Joanna Buffington, MD, MPH Division of Viral Hepatitis National Immunization
More informationTargeted Outreach & Other Strategies for Increasing HCV Testing
Targeted Outreach & Other Strategies for Increasing HCV Testing Working in Settings that Serve High-Risk Populations Webcast 2.4 Presented By: Denise Stinson, MN, RN Tacoma-Pierce County Health Department
More informationPREVENTION OF HCV IN PEOPLE WHO INJECT DRUGS
PREVENTION OF HCV IN PEOPLE WHO INJECT DRUGS Holly Hagan, PhD Professor Co-Director, Center for Drug Use and HIV Research Principal Investigator, HCV Synthesis Project New York University HCV prevalence
More informationChad Sabora, BS, MS, JD Missouri Network for Opiate Reform and Recovery. Drug Policy, Harm Reduction, and What s Next
Chad Sabora, BS, MS, JD Missouri Network for Opiate Reform and Recovery Drug Policy, Harm Reduction, and What s Next The start or lack thereof of Drug Policy in the United States The Harrison Narcotics
More informationTesting, Prevention and Care IDU in Chicago, 2009
HIV/HCV Risk Behaviors, Testing, Prevention and Care IDU in Chicago, 2009 Nik Prachand Britt Livak HIV Behavioral Surveillance IDU2 Cycle Surveillance, Epidemiology and Research Division of STI/HIV/AIDS
More informationHepatitis C COLVILLE FOCUSED DIAGNOSIS, MANAGEMENT, TREATMENT
Hepatitis C COLVILLE FOCUSED DIAGNOSIS, MANAGEMENT, TREATMENT Background and affiliations BS (MIT); 3 years in international health (Mexico City and Honduras with Peace Corps); MS (Colorado State University);
More informationHepatitis A and B outbreaks in Massachusetts,
Hepatitis A and B outbreaks in Massachusetts, 2017-2018 Shauna Onofrey, MPH Viral Hepatitis Surveillance Coordinator Massachusetts Department of Public Health Massachusetts Background Population: 6.86
More informationThe Syndemics of HIV, Hepatitis, and Overdose
The Syndemics of HIV, Hepatitis, and Overdose Sara Zeigler Associate Director for Policy Office of Policy, Planning and Partnerships (proposed) Centers for Disease Control and Prevention National Center
More informationOverview of Evidence for Sterile Syringe Access. Hilary McQuie Western Director Harm Reduction Coalition
Overview of Evidence for Sterile Syringe Access Hilary McQuie Western Director Harm Reduction Coalition Working Definition of Harm Reduction Harm Reduction: A set of practical, public health strategies
More informationHepatitis C in Massachusetts Epidemiology and Public Health Response
Massachusetts Department of Public Health Bureau of Infectious Disease and Laboratory Sciences Hepatitis C in Massachusetts Epidemiology and Public Health Response Shauna Onofrey, MPH, Viral Hepatitis
More informationUNAIDS 99.1E (English original, March 1999) This document, presenting a speech given at the United Nations General Assembly Special Session on Drugs,
U N A I D S B E S T P R A C T I C E C O L L E C T I O N Drug use and HIV/AIDS UNAIDS statement presented at the United Nations General Assembly Special Session on Drugs Joint United Nations Programme on
More informationJefferson County Syringe Exchange Program (SEP) Annual Report 2017
615 Sheridan Street Port Townsend, WA 98368 www.jeffersoncountypublichealth.org Jefferson County Syringe Exchange Program (SEP) Annual Report Jefferson County Public Health has provided a Syringe Exchange
More informationAmanda Archer, BS, MPH
Amanda Archer, BS, MPH The Need Hepatitis C Canton City Stark County From 2010 to 2016, Stark County has seen a 37.4% increase in the total number of newly diagnosed Hepatitis C. Canton City shows a 30%
More informationHIV and Hepatitis C Infection among Persons who Inject Drugs: Global Overview and Policy Implications
HIV and Hepatitis C Infection among Persons who Inject Drugs: Global Overview and Policy Implications Don Des Jarlais, Ph.D. Professor of Psychiatry, Icahn School of Medicine at Mount Sinai UNODC 2014
More informationNational HIV Behavioral Surveillance Portland, Oregon
National HIV Behavioral Surveillance Portland, Oregon Tim W. Menza, MD, PhD Medical Director HIV/STD/TB Section Oregon Health Authority timothy.w.menza@state.or.us National HIV Behavioral Surveillance
More informationWorking with People Who Use Drugs in HIV Care Settings. August 29, 2017 Workshop C 2:00 3:30 p.m.
Working with People Who Use Drugs in HIV Care Settings August 29, 2017 Workshop C 2:00 3:30 p.m. Working with People Who Use Drugs in HIV Care Settings Facilitator: Liz Hall, CDPH Office of AIDS Matt Curtis,
More informationState and Local Policies Regarding IDUs' Access to Sterile Syringes December 2005
State and Local Policies Regarding IDUs' Access to Sterile Syringes December 2005 In many cities and states, laws and regulations make possession of syringes a crime and limit IDUs' ability to legally
More informationNew Jersey HIV/AIDS Epidemiologic Profile 2011
New Jersey HIV/AIDS Epidemiologic Profile 2011 HIV/AIDS in New Jersey New Jersey ranks 5th among 46 states with long-term namebased reporting in the rate of HIV (not AIDS) infection among adults and adolescents
More informationReducing opioid overdose mortality: role of communityadministered
Reducing opioid overdose mortality: role of communityadministered naloxone Vennus Ballen, MD, MPH; Lara Maldjian, MPH New York City Department of Health and Mental Hygiene Clinical Director s Network (CDN)
More informationAddiction Therapy-2014
Addiction Therapy-2014 Chicago, USA August 4-6, 2014 Cynthia Stuhlmiller Harm Reduction, New Recovery and Addiction Therapy Cynthia Stuhlmiller, Professor of Rural Nursing University of New England, Armidale,
More informationThe National Infrastructure for Hepatitis C: Is There Anyone Home? December 21, 2015
The National Infrastructure for Hepatitis C: Is There Anyone Home? December 21, 2015 December 21, 2015 2 December 21, 2015 3 Can we eliminate hepatitis C? Treatments December 21, 2015 4 We Have the Roadmap
More informationPromoting hepatitis B vaccination
Promoting hepatitis B vaccination Introduction Hepatitis B is a serious blood borne infection that can exacerbate hepatitis C infection, can cause serious liver damage and sometimes results in death. Hepatitis
More informationHarm Reduction and Syringe Exchange Programs in the City and County of Los Angeles
Harm Reduction and Syringe Exchange Programs in the City and County of Los Angeles Stephen David Simon, JD City of Los Angeles, AIDS Coordinator s Office Anna Long, PhD, MPH County of Los Angeles, Department
More informationAlabama s Emerging Hepatitis C Epidemic and Vulnerability to an Outbreak of HIV Infection Among Persons Who Inject Drugs
Alabama s Emerging Hepatitis C Epidemic and Vulnerability to an Outbreak of HIV Infection Among Persons Who Inject Drugs James W. Galbraith MD Associate Professor Department of Emergency Medicine UAB Medicine
More informationViral Hepatitis. WHO Regional Office for Europe July 2013
Viral Hepatitis WHO Regional Office for Europe July 2013 What is Hepatitis? Hepatitis is a viral infection that causes inflammation of the liver There are five main types of viral hepatitis: A, B, C, D,
More informationSummary Report: Survey of Hepatitis C Virus counseling and testing services at HIV counseling and testing sites, and health service sites.
Summary Report: Survey of Hepatitis C Virus counseling and testing services at HIV counseling and testing sites, and health service sites. Sharon Adler MD, MPH Tomás Aragón MD, MPH Preventive Medicine
More informationHousing / Lack of Housing and HIV Prevention and Care
Housing / Lack of Housing and HIV Prevention and Care Evidence and Explanations Angela A. Aidala, PhD Columbia University Mailman School of Public Health Center for Homeless Prevention Studies WOMEN AS
More informationMOBILE OUTREACH. A guide to help plan and implement a Mobile Outreach Vehicle (MOV)-based risk reduction intervention program.
This guide is designed to help Community-Based Organizations (CBOs) and other individuals or groups in the planning and implementation of a Mobile Outreach Vehicle (MOV)-based risk-reduction intervention
More informationNeedle exchange programs
Needle exchange programs What science tells us about needle exchange programs Kerstin Käll, MD, PhD University of Linköping, Sweden Klas Rönnbäck, Ulrich Hermansson, Sten Rönnberg HIV and Injecting Drug
More information2 nd Meeting on detecting and responding to outbreaks of HIV among PWID
2 nd Meeting on detecting and responding to outbreaks of HIV among PWID Update on country situation: AUSTRIA Lisbon, 12 th October 201 Epidemiological update 2 HIV notifications in PWID Number of HIV cases
More informationNIH Public Access Author Manuscript Am J Public Health. Author manuscript; available in PMC 2011 August 1.
NIH Public Access Author Manuscript Published in final edited form as: Am J Public Health. 2010 August ; 100(8): 1449 1453. doi:10.2105/ajph.2009.178467. Syringe Sharing and HIV Incidence Among Injection
More informationImplementation of testing (and other interventions along the Continuum of Care)
Implementation of testing (and other interventions along the Continuum of Care) Jonathan Mermin, MD, MPH National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention U.S. Centers for Disease Control
More informationHIV/AIDS Prevention, Treatment and Care among Injecting Drug Users and in Prisons
HIV/AIDS Prevention, Treatment and Care among Injecting Drug Users and in Prisons Ministerial Meeting on Urgent response to the HIV/AIDS epidemics in the Commonwealth of Independent States Moscow, 31 March
More informationTime to Eliminate Hepatitis B John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention
Time to Eliminate Hepatitis B John W. Ward, M.D. Division of Viral Hepatitis Centers for Disease Control and Prevention Division of Viral Hepatitis National Center for HIV/AIDS, Viral Hepatitis, STD, and
More informationHarm Reduction in Nigeria
Harm Reduction in Nigeria Needs, gaps, and responses to ensure access to effective HIV prevention, treatment and care for people who inject drugs February 2018 This document is made possible by the generous
More informationTobacco Use. Overview. General Data Note. Summary NYSDOH
Tobacco Use * Note: For interpretation purposes, please print this report and supplemental document in color Overview Smoking is a leading cause of preventable death and can also cause many illnesses,
More informationPERFORMANCE AND IMAGE ENHANCING DRUGS
PERFORMANCE AND IMAGE ENHANCING DRUGS Injectors access to needle syringe programs Presented at the 2014 National Drug Trends Conference Sydney 20 October 2014 Dr Karen J Chronister Overview Background
More informationGuidelines For Services Providing Injecting Equipment
Guidelines For Services Providing Injecting Equipment Best Practice Recommendations For Commissioners and Injecting Equipment Provision (IEP) Services in Scotland (Scottish Government 2010) January 2014
More informationRISE Needle Exchange Program
PHOENIX RECOVERY SERVICES, LLC RISE Needle Exchange Program FUNDED BY SKAGIT COUNTY PUBLIC HEALTH AND COMMUNITY SERVICES RISE REFERRAL INTERVENTION SAFETY EDUCATION Needle Exchange Programs : Myth vs.
More informationNeedle and Syringe Programs - 17 October 2013
Needle and Syringe Programs - 17 October 2013 ANCD Position Paper: Needle and Syringe Programs MEDIA RELEASE 17 October 2013 The Australian National Council on Drugs (ANCD) has today released a position
More informationHepatitis B Virus and the Opioid Crisis
Hepatitis B Virus and the Opioid Crisis Alice Asher, RN, Ph.D. Epidemiology and Surveillance Branch Division of Viral Hepatitis National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Centers
More informationWhat is injection drug use?
What is injection drug use? Essential Standards 7.ATOD.1 Understand the health risks associated with alcohol, tobacco, and other drug use. Clarifying Objectives 7.ATOD.1.2 - Explain health risks resulting
More informationINTEGRATED HCV SCREENING AND TESTING IN SUBSTANCE ABUSE TREATMENT
INTEGRATED HCV SCREENING AND TESTING IN SUBSTANCE ABUSE TREATMENT HEPATITIS Hepatitis is the name for a family of viral infections that affect the liver. The most common types are Hepatitis A, B, and C.
More informationWA DRUG ABUSE STRATEGY OFFICE
WA DRUG ABUSE STRATEGY OFFICE WA Drug Abuse Strategy Office Statistical Bulletin Number 6, February 2 Statistical Bulletin Number 6, February 2 DISTRIBUTION OF NEEDLES & SYRINGES IN WA, 1987-19 Introduction
More informationHarm Reduction and Medical Respite (Dead People Don t Recover) Alice Moughamian, RN,CNS Dave Munson MD
Harm Reduction and Medical Respite (Dead People Don t Recover) Alice Moughamian, RN,CNS Dave Munson MD Objectives Provide an overview of harm reduction by defining shared language and key terms. Collaboratively
More informationResearch on opioid overdose and naloxone distribution in San Francisco: from epidemiology to intervention development to implementation.
Research on opioid overdose and naloxone distribution in San Francisco: from epidemiology to intervention development to implementation. Alex H. Kral, PhD Director Behavioral and Urban Health Program RTI
More information26/09/2014. Types of Viral Hepatitis. Prevention of Viral Hepatitis as a Health Disparity for American Indians: Successes and Challenges
Rate per, Types of Viral Hepatitis A E B D C Prevention of Viral Hepatitis as a Health Disparity for American Indians: Successes and Challenges Source of virus Feces Feces Blood/bloodderived body fluids
More informationPlacing the United States on the Path Toward the Elimination of Hepatitis C as a Public Health Threat
Placing the United States on the Path Toward the Elimination of Hepatitis C as a Public Health Threat John W. Ward, M.D Division of Viral Hepatitis National Center for HIV/AIDS, Viral Hepatitis, STD &
More informationHIV Risk Behaviour in Irish Intravenous Drug Users
Abstract HIV Risk Behaviour in Irish Intravenous Drug Users A. Dorman, E. Keenan, C. Schuttler, J. Merry, J. J. O Connor The Drug Treatment Centre Board, Trinity Court, 30/31 Pearse Street, Dublin 2. The
More informationANNUAL PROJECT PROGRESS REPORT FOR 2008 (draft)
ANNUAL PROJECT PROGRESS REPORT FOR 2008 (draft) Project Title: HIV/AIDS prevention and care among injecting drug users and in prison settings in Estonia, Latvia and Lithuania Project Number: XEEJ20 Total
More informationDRUG POLICY ALLIANCE. Reason. Compassion. Justice.
DRUG POLICY ALLIANCE Reason. Compassion. Justice. www.drugpolicy.org NEW YORK WASH EXICO NEW JERSEY Do you think the war on drugs is doing more harm than good? Then join the nation's leading organization
More informationBlood-borne viruses in marginalised populations
Blood-borne viruses in marginalised populations 2 May 2014 SYDNEY MEDICAL SCHOOL Bethany White, PhD Discipline of Addiction Medicine Overview Blood-borne viruses: HIV Hepatitis B virus (HBV) Hepatitis
More informationSubstance Abuse Treatment, Integrated Care, & the HIV Care Continuum
Substance Abuse Treatment, Integrated Care, & the HIV Care Continuum Sherry Larkins, Ph.D. University of California, Los Angeles Integrated Substance Abuse Programs May 22, 2014 Does your agency offer
More informationKEY FINDINGS FROM THE 2005 MYRBS
4 CHAPTER 4 ILLEGAL DRUG USE INTRODUCTION Drug use costs taxpayers about $98 billion annually in preventable health care costs, extra law enforcement, auto crashes, crime, and lost productivity (4a). More
More informationResearch on Supervised Injection Facilities: A Review of the Literature
Research on Supervised Injection Facilities: A Review of the Literature What is a supervised injection facility? A supervised injection facility (SIF) is a formal venue intended for injection drug users
More informationStrategies to Reduce Harm and HIV/AIDS Infection among Drug Using Populations
cessation of use may be the most effective form of harm reduction but, in reality, many clients do not wish to cease using, or find it too difficult. (Addy & Ritter, 2000, p.1) Introduction Historically,
More informationWhat works: prevention for drug injectors. Holly Hagan Don C. Des Jarlais. Corina Lelutiu-Weinberger
What works: A synthesis of research on HCV prevention for drug injectors Holly Hagan Don C. Des Jarlais Enrique R. Pouget Corina Lelutiu-Weinberger Center for Drug Use and HIV Research NDRI New York, NY
More informationNational Viral Hepatitis Action Plan Priority Populations Approach
National Viral Hepatitis Action Plan Priority Populations Approach November 29, 2017 Corinna Dan, RN, MPH Office of HIV/AIDS and Infectious Disease Policy Office of the Assistant Secretary for Health Department
More informationLocal Legislative Approval and Program Certification
Syringe Services Programs: Implementation Brief St. Louis County, Missouri Introduction Syringe services programs (SSPs), also known as needle exchange or syringe access programs, are an integral component
More informationUpdate on Community-based harm reduction services in Nelson Mandela Bay 25/10/2018
Update on Community-based harm reduction services in Nelson Mandela Bay 25/10/2018 Overview Background to injecting drug use Overview of harm reduction Data on Hepatitis Summary of services provided by
More informationCOMMUNITY CONSULTATION SERIES Women Who Have Sex With Women (WSW) and HIV Prevention
COMMUNITY CONSULTATION SERIES Women Who Have Sex With Women (WSW) and HIV Prevention Presented by: The Institute @ Harm Reduction Coalition May 14, 2010 Harm Reduction Coalition Founded in 1994 to work
More informationSyringe type and HIV risk: current knowledge and future directions
Syringe type and HIV risk: current knowledge and future directions Presented by William A. Zule, Dr.PH Along with Georgiy V. Bobashev, Curtis M. Coomes, Don C. Des Jarlais, Samuel R. Friedman, V. Anna
More informationIntegration of collaborative TB/HIV activities with harm reduction services
Integration of collaborative TB/HIV activities with harm reduction services Maryna Zelenskaya Ph D State service on HIV/AIDS and other socially diseases control, Head of Department on HIV/AIDS combating
More informationHigh Impact HIV Prevention Services and Best Practices
High Impact HIV Prevention Services and Best Practices David W. Purcell, JD, PhD Deputy Director for Behavioral and Social Science Division of HIV/AIDS Prevention Centers for Disease Control and Prevention
More informationHIV EPIDEMIOLOGY IN NEW YORK CITY
HIV EPIDEMIOLOGY IN NEW YORK CITY Ellen Weiss Wiewel, MHS HIV Epidemiology and Field Services Program New York City Department of Health and Mental Hygiene http://www.nyc.gov/html/doh/html/dires/hivepi.shtml
More informationEMCDDA-update HIV/HCV among people who inject drugs: situation and response
EMCDDA-update HIV/HCV among people who inject drugs: situation and response Dagmar Hedrich EU Think Tank HIV/AIDS: 24-25 November 2015, Luxembourg Latest European overview Multi-indicator based analysis
More informationThe sharing of needles and syringes (hereafter syringes )
EPIDEMIOLOGY AND SOCIAL SCIENCE in Harlem and the Bronx During the New York State Expanded Syringe Access Demonstration Program Enrique R. Pouget, BA,* Sherry Deren, PhD,* Crystal M. Fuller, PhD, Shannon
More informationCOLLABORATIVE RESEARCH ON HIV AMONG PERSONS WHO INJECT DRUGS IN TALLINN, ESTONIA, PRESENT
COLLABORATIVE RESEARCH ON HIV AMONG PERSONS WHO INJECT DRUGS IN TALLINN, ESTONIA, 2005 - PRESENT DON C DES JARLAIS ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI ANNELI UUSKULA UNIVERSITY OF TARTU The number
More informationPart 1: Introduction & Overview
Part 1: Introduction & Overview We envision a collaborative, participative partnership around IDU that: Provides all relevant and interested stakeholders with a voice and role. Promotes awareness of the
More informationCivil Society Driven Response in Ukraine: A program making a difference and bringing results
Civil Society Driven Response in Ukraine: A program making a difference and bringing results CATIE Forum Making it work: From Planning to Practice October 16th, 2015 Andriy Klepikov International HIV/AIDS
More informationAddressing barriers and facilitators accessing treatment and retention in care among HIV-positive Mexican MSM
Addressing barriers and facilitators accessing treatment and retention in care among HIV-positive Mexican MSM Robyn Schweizer MSW, Bienestar Human Services, rschweizer@bienestar.org Jeff Bailey MPH, APLA
More informationAMERICA S OPIOID EPIDEMIC AND ITS EFFECT ON THE NATION S COMMERCIALLY-INSURED POPULATION PUBLISHED JUNE 29, 2017
AMERICA S OPIOID EPIDEMIC AND ITS EFFECT ON THE NATION S COMMERCIALLY-INSURED POPULATION PUBLISHED JUNE 29, 2017 America s Opioid Epidemic and Its Effect on the Nation s Commercially-Insured Population
More informationThe Geography of Infectious Diseases Related to the Opioid Epidemic. Patrick Sullivan, DVM, PhD Emory University March 12, 2018
The Geography of Infectious Diseases Related to the Opioid Epidemic Patrick Sullivan, DVM, PhD Emory University March 12, 2018 Presentation Outline The importance of infectious diseases in the opioid epidemic
More informationBassett Medical Center PPS Community Profile
Bassett Medical Center PPS Community Profile Counties served: Delaware, Herkimer, Madison, Otsego, and Schoharie DEMOGRAPHICS 1 The Bassett Medical Center PPS s total population is 278,214. Age: Residents
More informationHepatitis C Virus Infection Among Young Drug Users What Can Viral Hepatitis Coordinators and Health Departments Do?
Hepatitis C Virus Infection Among Young Drug Users What Can Viral Hepatitis Coordinators and Health Departments Do? Dan Church Massachusetts Department of Public Health Bureau of Infectious Disease 1 Goals
More informationDHMH Activities toward Implementing Requirements of Md. Code Ann., Health-General , Hepatitis C Prevention and Control within Maryland
DHMH Activities toward Implementing Requirements of Md. Code Ann., Health-General 18-1001, Hepatitis C Prevention and Control within Maryland Submitted by: Maryland Department of Health and Mental Hygiene
More informationThe epidemiology of hepatitis C in Canada
The epidemiology of hepatitis C in Canada FACT SHEET Published 2017 This fact sheet provides a snapshot of the hepatitis C epidemic in Canada. It is one of a series of fact sheets providing epidemiological
More informationMMWR Analysis Provides New Details on HIV Incidence in U.S. Populations
MMWR Analysis Provides New Details on HIV Incidence in U.S. Populations CDC HIV/AIDS Fa c t s S e p t e m b e r 2008 On August 6, 2008, the Centers for Disease Control and Prevention (CDC) released a new
More informationHarm Reduction 3/5/2019. Topics for Today. Working Definition of Harm Reduction. Scott Stokes Section Chief, Substance Abuse Services
Harm Reduction Scott Stokes Section Chief, Substance Abuse Services Topics for Today Overview of harm reduction Sterile syringe access programs Preventing fatal opioid overdoses Working Definition of Harm
More informationUpdate Report # 45. Patterns of Sexual Behaviors and Sexual Risk among HIV Positive People in New York City
Update Report # 45 Patterns of Sexual Behaviors and Sexual Risk among HIV Positive People in New York City Angela A. Aidala Mary Ann Chiasson Gunjeong Lee Center for Applied Public Health Joseph L. Mailman
More informationHepatitis C in Massachusetts Michael Gaucher and Shauna Onofrey MA Department of Public Health Bureau of Infectious Disease & Laboratory Sciences
Massachusetts Department of Public Health Bureau of Infectious Disease and Laboratory Sciences Hepatitis C in Massachusetts Michael Gaucher and Shauna Onofrey MA Department of Public Health Bureau of Infectious
More informationAge-Adjusted Rates of Death Related to POs and Heroin,
Learning Objectives Upon completion, participants should be able to: Incorporate available tools to screen patients for IDU into routine practice Develop processes to mitigate infectious diseases risks
More informationSeptember 1, The Honorable Tom Price, MD Secretary Department of Health and Human Services 200 Independence Avenue SW Washington, DC 20201
September 1, 2017 The Honorable Tom Price, MD Secretary Department of Health and Human Services 200 Independence Avenue SW Washington, DC 20201 Dear Secretary Price: The National Association of County
More informationHIV Prevention Prioritization & Implementation Brief: Gombe State
HIV Prevention Prioritization & Implementation Brief: Gombe State Introduction The HIV epidemic in Nigeria is complex, with substantial heterogeneity in HIV prevalence across different regions and diverse
More informationNew South Wales Needle and Syringe Program Enhanced Data Collection
New South Wales Needle and Syringe Program Enhanced Data Collection 2017 A report for the NSW Ministry of Health by the Kirby Institute, UNSW Australia August 2017 Prepared by Ms Louise Geddes, Dr Jenny
More informationAdditional North Carolina Projects
Additional North Carolina Projects William Zule, Dr.P.H. www.rti.org RTI International is a trade name of Research Triangle Institute Risk Groups Injecting drug users (IDUs) Non-injecting drug users (non-idus)
More informationTraining Objectives. By the end of this session you will be able to: 2. Recognize key principles of harm reduction.
Training Objectives By the end of this session you will be able to: 1. Define harm reduction. 2. Recognize key principles of harm reduction. 3. Identify the need for harm reduction, with a PWID focus.
More information